[go: up one dir, main page]

TW200510437A - Phosphinane compound with immunomodulating activity - Google Patents

Phosphinane compound with immunomodulating activity

Info

Publication number
TW200510437A
TW200510437A TW093124155A TW93124155A TW200510437A TW 200510437 A TW200510437 A TW 200510437A TW 093124155 A TW093124155 A TW 093124155A TW 93124155 A TW93124155 A TW 93124155A TW 200510437 A TW200510437 A TW 200510437A
Authority
TW
Taiwan
Prior art keywords
compound
phosphinane
immunomodulating activity
activity
immunomodulating
Prior art date
Application number
TW093124155A
Other languages
Chinese (zh)
Inventor
Masao Chino
Kunitomo Adachi
Yoshihito Tanaka
Kunio Sugahara
Hirofumi Matsuyuki
Ayumi Tomatsu
Masatoshi Kiuchi
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of TW200510437A publication Critical patent/TW200510437A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657109—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms esters of oxyacids of phosphorus in which one or more exocyclic oxygen atoms have been replaced by (a) sulfur atom(s)
    • C07F9/657118—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms esters of oxyacids of phosphorus in which one or more exocyclic oxygen atoms have been replaced by (a) sulfur atom(s) non-condensed with carbocyclic rings or heterocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention is directed to a phosphinane compound having a unique immunomodulating activity, a process for a preparation thereof, a pharmaceutical composition containing the same, and a method of preventing or treating disorders or diseases mediated by T lymphocytes by administering the compound to a subject in need of treatment.
TW093124155A 2003-08-12 2004-08-12 Phosphinane compound with immunomodulating activity TW200510437A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49454303P 2003-08-12 2003-08-12

Publications (1)

Publication Number Publication Date
TW200510437A true TW200510437A (en) 2005-03-16

Family

ID=34135347

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093124155A TW200510437A (en) 2003-08-12 2004-08-12 Phosphinane compound with immunomodulating activity

Country Status (2)

Country Link
TW (1) TW200510437A (en)
WO (1) WO2005014603A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101905023B (en) 2004-07-16 2012-07-11 杏林制药株式会社 Effective method of using medicine and method related to prevention of occurrence of side effects
RU2376285C2 (en) 2004-10-12 2009-12-20 Киорин Фармасьютикал Ко., Лтд. Process of producing 2-amino-2[2-[4(3-benzyloxyphenylthio)-2-chlorophenylethyl]-1, 3-propanediol] hydrochloride and hydrates thereof, as well as intermediate products for producing said hydrates
PL1932522T3 (en) 2005-10-07 2012-09-28 Kyorin Seiyaku Kk Therapeutic agent for liver disease containing 2-amino-1,3-propanediol derivative as active ingredient
TWI389683B (en) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
WO2008018447A1 (en) 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
SI2058317T1 (en) 2006-08-08 2014-01-31 Kyorin Pharmaceutical Co., Ltd. Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
EP2744776A1 (en) 2011-08-19 2014-06-25 Westfälische Wilhelms-Universität Münster New ligands for targeting of s1p receptors for in vivo imaging and treatment of diseases
WO2017099822A1 (en) * 2015-12-08 2017-06-15 Retrophin, Inc. Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders
GB201715786D0 (en) 2017-09-29 2017-11-15 Univ College Cardiff Consultants Ltd Compounds
US11696904B2 (en) * 2020-01-10 2023-07-11 The Regents Of The University Of California Prodrug for therapeutic applications

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001285331B2 (en) * 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents

Also Published As

Publication number Publication date
WO2005014603A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
TW200505416A (en) Bi-aryl compound having immunosuppressive activity
IL267381A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
JO2373B1 (en) W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
WO2003092580A3 (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
WO2004041258A8 (en) Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
TR200201094T2 (en) Bicyclic amino acids as pharmaceuticals
NO20045056L (en) Methods for the treatment of hepatitis
TNSN07208A1 (en) 3,5-DISUBTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d] PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
DE60216830D1 (en) Pharmaceutical compositions for the treatment of disorders of the CNS or other diseases
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
TW200510437A (en) Phosphinane compound with immunomodulating activity
IL163951A0 (en) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
EP1597234A4 (en) Novel compounds
WO2003072019A3 (en) Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog
PL375354A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
UA30659A (en) Method for reduction of drug dependence
UA91697C2 (en) 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF